ERYTECH Presents New Preclinical Anti-Tumor Data on erymethionase at AACR 2017

ERYTECH today announced the presentation of new anti-tumor data supporting the Company’s preclinical product erymethionase (ERY-MET) at the upcoming American Association for Cancer Research (AACR) Annual Meeting, being held April 1 – 5, 2017 in Washington, D.C.

Menu